Citizens JMP analyst Roy Buchanan initiated coverage of Assembly Biosciences (ASMB) with an Outperform rating and $38 price target The firm believes the company’s “strong early data point to likely best-in-class profiles” for both its oral candidates for treating herpes simplex virus is underappreciated at current share levels. Assembly’s lead opportunity in treating recurrent genital herpes has blockbuster potential, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASMB:
- Assembly Biosciences price target raised to $39 from $31 at Guggenheim
- Four new option listings and one option delisting on August 27th
- Assembly Biosciences assumed with a Buy at H.C. Wainwright
- Assembly Biosciences Completes $175 Million Equity Financing
- Assembly Biosciences Announces Positive Phase 1b Results